Loading...

Achaogen

DB:1A1
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1A1
DB
$11M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • Achaogen has significant price volatility in the past 3 months.
1A1 Share Price and Events
7 Day Returns
-60%
DB:1A1
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-98.4%
DB:1A1
-9.2%
DE Biotechs
-6.7%
DE Market
1A1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Achaogen (1A1) -60% -61.4% -86.1% -98.4% -95% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 1A1 underperformed the Biotechs industry which returned -9.2% over the past year.
  • 1A1 underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
1A1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Achaogen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Achaogen to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Achaogen.

DB:1A1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 12.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:1A1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (445.84%))
4.742
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (2 * 5.96%)
12.15%

Discounted Cash Flow Calculation for DB:1A1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Achaogen is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:1A1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 12.15%)
2019 -110.17 Analyst x1 -98.24
2020 -74.81 Analyst x1 -59.48
2021 -31.48 Analyst x1 -22.31
2022 21.46 Analyst x1 13.56
2023 81.63 Analyst x1 46.01
2024 138.74 Est @ 69.96% 69.73
2025 206.77 Est @ 49.04% 92.67
2026 277.89 Est @ 34.4% 111.06
2027 344.99 Est @ 24.15% 122.94
2028 403.54 Est @ 16.97% 128.22
Present value of next 10 years cash flows $404.17
DB:1A1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $403.54 × (1 + 0.23%) ÷ (12.15% – 0.23%)
$3,393.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,393.09 ÷ (1 + 12.15%)10
$1,078.15
DB:1A1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $404.17 + $1,078.15
$1,482.32
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,482.32 / 63.88
$23.2
DB:1A1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:1A1 represents 0.91533x of NasdaqGM:AKAO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.91533x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 23.20 x 0.91533
€21.24
Value per share (EUR) From above. €21.24
Current discount Discount to share price of €0.16
= -1 x (€0.16 - €21.24) / €21.24
99.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Achaogen is available for.
Intrinsic value
>50%
Share price is €0.16 vs Future cash flow value of €21.24
Current Discount Checks
For Achaogen to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Achaogen's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Achaogen's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Achaogen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Achaogen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1A1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-4.11
NasdaqGM:AKAO Share Price ** NasdaqGM (2019-04-18) in USD $0.17
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Achaogen.

DB:1A1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:AKAO Share Price ÷ EPS (both in USD)

= 0.17 ÷ -4.11

-0.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Achaogen is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Achaogen is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Achaogen's expected growth come at a high price?
Raw Data
DB:1A1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.04x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
63.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Achaogen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Achaogen's assets?
Raw Data
DB:1A1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.13
NasdaqGM:AKAO Share Price * NasdaqGM (2019-04-18) in USD $0.17
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:1A1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:AKAO Share Price ÷ Book Value per Share (both in USD)

= 0.17 ÷ -0.13

-1.34x

* Primary Listing of Achaogen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Achaogen has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Achaogen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Achaogen has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Achaogen expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Achaogen expected to grow at an attractive rate?
  • Achaogen's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Achaogen's earnings growth is expected to exceed the Germany market average.
  • Achaogen's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1A1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1A1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 63.2%
DB:1A1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 45.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1A1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1A1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 265 112 2
2022-12-31 167 12 2
2021-12-31 67 -45 3
2020-12-31 31 -59 5
2019-12-31 12 -84 5
DB:1A1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 9 -165 -187
2018-09-30 9 -166 -175
2018-06-30 7 -151 -163
2018-03-31 6 -129 -140
2017-12-31 11 -95 -126
2017-09-30 20 -75 -119
2017-06-30 36 -56 -100
2017-03-31 43 -51 -92
2016-12-31 42 -47 -71
2016-09-30 36 -46 -53
2016-06-30 24 -42 -50
2016-03-31 27 -27 -33

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Achaogen's earnings are expected to grow significantly at over 20% yearly.
  • Achaogen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1A1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Achaogen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1A1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.34 2.84 -0.17 2.00
2022-12-31 0.13 0.78 -0.53 2.00
2021-12-31 -0.73 -0.36 -0.92 3.00
2020-12-31 -0.89 -0.46 -1.30 5.00
2019-12-31 -1.30 -0.80 -1.92 6.00
DB:1A1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -4.11
2018-09-30 -3.96
2018-06-30 -3.76
2018-03-31 -3.34
2017-12-31 -3.17
2017-09-30 -3.29
2017-06-30 -3.10
2017-03-31 -3.29
2016-12-31 -3.00
2016-09-30 -2.50
2016-06-30 -2.66
2016-03-31 -1.81

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Achaogen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Achaogen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Achaogen has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Achaogen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Achaogen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Achaogen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Achaogen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Achaogen's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Achaogen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Achaogen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1A1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 8.73 -186.51 71.39
2018-09-30 8.57 -175.37 68.97
2018-06-30 7.15 -163.49 61.84
2018-03-31 5.86 -139.59 50.22
2017-12-31 11.18 -125.62 41.90
2017-09-30 20.04 -118.96 32.35
2017-06-30 35.51 -100.09 25.00
2017-03-31 43.39 -92.29 20.10
2016-12-31 41.77 -71.23 17.12
2016-09-30 35.70 -52.77 15.48
2016-06-30 24.13 -50.49 14.02
2016-03-31 27.03 -33.11 12.95
2015-12-31 26.06 -27.09 12.41
2015-09-30 25.66 -20.68 11.63
2015-06-30 25.70 -20.23 10.80
2015-03-31 18.86 -22.90 10.26
2014-12-31 19.97 -20.18 9.65
2014-09-30 21.90 -17.81 8.39
2014-06-30 21.67 -12.06 7.72
2014-03-31 20.97 -12.81 7.14
2013-12-31 18.51 -13.11 6.67
2013-09-30 16.29 -12.51 6.87 1.64
2012-12-31 17.94 -18.37 7.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Achaogen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Achaogen has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Achaogen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Achaogen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Achaogen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Achaogen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Achaogen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Achaogen's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Achaogen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Achaogen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Achaogen has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Achaogen Company Filings, last reported 3 months ago.

DB:1A1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -6.29 49.78 30.96
2018-09-30 24.79 24.77 58.22
2018-06-30 58.92 24.62 100.54
2018-03-31 103.09 24.47 144.00
2017-12-31 121.96 21.96 164.79
2017-09-30 153.28 24.87 199.40
2017-06-30 178.51 25.70 230.29
2017-03-31 78.64 25.48 132.04
2016-12-31 106.74 25.28 145.88
2016-09-30 31.02 25.02 61.09
2016-06-30 37.51 24.82 70.00
2016-03-31 31.84 14.67 49.49
2015-12-31 43.16 14.54 58.73
2015-09-30 53.61 14.41 70.44
2015-06-30 60.26 0.00 61.27
2015-03-31 60.05 0.00 61.65
2014-12-31 64.61 0.00 63.68
2014-09-30 68.16 0.00 72.03
2014-06-30 75.85 0.00 74.50
2014-03-31 78.85 5.54 84.94
2013-12-31 7.95 6.69 10.74
2013-09-30 -0.03 7.79 8.21
2012-12-31 -11.99 18.98 7.07
  • Achaogen has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Achaogen's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Achaogen has less than a year of cash runway based on current free cash flow.
  • Achaogen has less than a year of cash runway if free cash flow continues to grow at historical rates of 63.9% each year.
X
Financial health checks
We assess Achaogen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Achaogen has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Achaogen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Achaogen dividends.
If you bought €2,000 of Achaogen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Achaogen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Achaogen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1A1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1A1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Achaogen has not reported any payouts.
  • Unable to verify if Achaogen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Achaogen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Achaogen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Achaogen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Achaogen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Achaogen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Achaogen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Blake Wise
COMPENSATION $2,701,614
AGE 47
TENURE AS CEO 1.3 years
CEO Bio

Mr. Blake Wise has been Principal Financial Officer and Principal Accounting Officer of Achaogen, Inc since April 15, 2019. He has been the Chief Executive Officer and Director of Achaogen, Inc. since January 1, 2018. Mr. Wise served as Chief Operating Officer of Achaogen, Inc. from October 1, 2015 to December 31, 2017 and its President from February 23, 2017 to December 31, 2017. Mr. Wise is joining Achaogen after 13 years at Genentech, a biotechnology company. He established and led the Cross BioOncology franchise as Vice President, Cross BioOncology. Prior to joining Genentech in 2002, Mr. Wise worked in consumer marketing, e-commerce and online marketing outside of the healthcare industry in leadership positions at Gap and Webvan. During his time at Genentech, Mr. Wise held several other leadership positions of increasing responsibility, including Senior Director, Franchise Head and Life Cycle Leader of the Lytics franchise, with overall commercial responsibility for Genentech’s hospital-based Lytics business. He previously served as a Sales Director in BioOncology, Marketing Director in Cystic Fibrosis and Immunology and Interactive Marketing Director where he built Genentech’s digital marketing capabilities. Prior to joining Genentech in 2002, Mr. Wise worked in consumer marketing, e-commerce and online marketing outside of the healthcare industry in leadership positions at Gap, Inc. and Webvan. He has been a Director of Calithera Biosciences, Inc. since September 21, 2017. Mr. Wise received his Bachelor of Arts degree in Business Economics from University of California, Santa Barbara and his Masters of Business Administration degree from UC Berkeley's Haas School of Business.

CEO Compensation
  • Blake's compensation has increased whilst company is loss making.
  • Blake's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Achaogen management team in years:

1.3
Average Tenure
48
Average Age
  • The average tenure for the Achaogen management team is less than 2 years, this suggests a new team.
Management Team

Blake Wise

TITLE
CEO, Principal Financial Officer
COMPENSATION
$3M
AGE
47
TENURE
1.3 yrs

Gary Loeb

TITLE
General Counsel
COMPENSATION
$458K
AGE
48
TENURE
1.3 yrs

Liz Bhatt

TITLE
Chief Business Officer & COO
AGE
49
TENURE
0.8 yrs

Jeannie Lloyds

TITLE
Vice President of Sales
TENURE
1.7 yrs

Janet Dorling

TITLE
Chief Commercial Officer
TENURE
2.2 yrs
Board of Directors Tenure

Average tenure and age of the Achaogen board of directors in years:

4.1
Average Tenure
60
Average Age
  • The tenure for the Achaogen board of directors is about average.
Board of Directors

Bryan Roberts

TITLE
Chairman of the Board
COMPENSATION
$207K
AGE
51
TENURE
9.3 yrs

Blake Wise

TITLE
CEO, Principal Financial Officer
COMPENSATION
$3M
AGE
47
TENURE
1.3 yrs

John Doyle

TITLE
Independent Director
COMPENSATION
$185K
AGE
50
TENURE
6.4 yrs

John Smither

TITLE
Independent Director
COMPENSATION
$197K
AGE
65
TENURE
5.3 yrs

Kent Lieginger

TITLE
Independent Director
COMPENSATION
$184K
AGE
67
TENURE
4.1 yrs

Greg Stea

TITLE
Independent Director
COMPENSATION
$181K
AGE
60
TENURE
3.8 yrs

Karen Bernstein

TITLE
Independent Director
COMPENSATION
$333K
AGE
65
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • Achaogen insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Apr 19 Sell Robert W. Duggan Foundation., Endowment Arm Company 10. Apr 19 10. Apr 19 -100,000 €0.44 €-43,522
12. Apr 19 Sell Robert Duggan Individual 08. Apr 19 11. Apr 19 -301,700 €0.47 €-134,722
05. Apr 19 Sell Robert Duggan Individual 29. Mar 19 03. Apr 19 -936,398 €0.42 €-363,416
28. Mar 19 Sell Genius Inc. Company 21. Mar 19 21. Mar 19 -72,000 €0.48 €-34,903
28. Mar 19 Sell Robert Duggan Individual 21. Mar 19 28. Mar 19 -1,365,288 €0.49 €-604,741
20. Mar 19 Sell Robert Duggan Individual 18. Mar 19 20. Mar 19 -1,277,888 €0.49 €-603,664
13. Mar 19 Sell Robert Duggan Individual 11. Mar 19 13. Mar 19 -2,354,007 €0.56 €-1,258,209
26. Feb 19 Sell Blake Wise Individual 21. Feb 19 21. Feb 19 -3,771 €0.79 €-2,961
26. Feb 19 Sell Elizabeth Bhatt Individual 21. Feb 19 21. Feb 19 -971 €0.79 €-762
26. Feb 19 Sell Janet Dorling Individual 21. Feb 19 21. Feb 19 -1,063 €0.79 €-835
26. Feb 19 Sell Zeryn Sarpangal Individual 21. Feb 19 21. Feb 19 -1,388 €0.79 €-1,090
26. Feb 19 Sell Gary Loeb Individual 21. Feb 19 21. Feb 19 -791 €0.79 €-621
08. Feb 19 Sell Janet Dorling Individual 05. Feb 19 05. Feb 19 -818 €1.18 €-968
12. Dec 18 Buy Robert Duggan Individual 10. Dec 18 11. Dec 18 743,348 €1.45 €1,062,192
11. Dec 18 Buy Robert Duggan Individual 07. Dec 18 07. Dec 18 22,431 €1.23 €27,545
27. Nov 18 Buy Robert Duggan Individual 23. Nov 18 27. Nov 18 157,760 €1.67 €249,362
23. Nov 18 Buy Robert Duggan Individual 20. Nov 18 20. Nov 18 231,495 €1.69 €392,196
20. Nov 18 Buy Robert Duggan Individual 19. Nov 18 19. Nov 18 4,648 €1.41 €6,570
28. Sep 18 Sell Blake Wise Individual 25. Sep 18 25. Sep 18 -3,242 €3.53 €-11,429
28. Sep 18 Sell Gary Loeb Individual 25. Sep 18 25. Sep 18 -1,038 €3.53 €-3,659
28. Jun 18 Sell Janet Dorling Individual 26. Jun 18 26. Jun 18 -450 €8.22 €-3,698
28. Jun 18 Sell Blake Wise Individual 26. Jun 18 26. Jun 18 -1,194 €8.22 €-9,812
28. Jun 18 Sell Tobin Schilke Individual 26. Jun 18 26. Jun 18 -298 €8.22 €-2,449
28. Jun 18 Sell Gary Loeb Individual 26. Jun 18 26. Jun 18 -324 €8.22 €-2,663
28. Jun 18 Sell Kenneth Hillan Individual 26. Jun 18 26. Jun 18 -744 €8.22 €-6,114
13. Jun 18 Sell Tobin Schilke Individual 11. Jun 18 11. Jun 18 -2,087 €10.12 €-21,121
07. May 18 Buy Robert Duggan Individual 03. May 18 03. May 18 976,880 €9.66 €9,260,730
27. Apr 18 Buy Robert Duggan Individual 25. Apr 18 27. Apr 18 230,096 €10.76 €2,467,448
23. Apr 18 Buy Robert Duggan Individual 19. Apr 18 23. Apr 18 468,337 €10.83 €5,008,119
X
Management checks
We assess Achaogen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Achaogen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Details
Name: Achaogen, Inc.
1A1
Exchange: DB
Founded: 2002
$9,933,472
63,879,995
Website: http://www.achaogen.com
Address: Achaogen, Inc.
1 Tower Place,
Suite 400,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM AKAO Common Stock Nasdaq Global Market US USD 12. Mar 2014
DB 1A1 Common Stock Deutsche Boerse AG DE EUR 12. Mar 2014
Number of employees
Current staff
Staff numbers
42
Achaogen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:19
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/05
Last earnings filing: 2019/04/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.